Company intelligence
52North
Transforming urgent care pathways for patients globally
About 52North
52North is a medical technology company on a mission to make urgent care pathways safer and more effective. Awarded breakthrough status for its first product Neutrocheck® by the UK Government in 2024, 52North builds in vitro diagnostic and digital solutions to transform patient journeys in urgent care. Its award-winning, multidisciplinary team is based in Cambridge, UK. 52North is backed by leading UK and US hospital venture funds, Meridian Health Ventures and Cedars-Sinai Intellectual Property company, and other partners, including the University of Cambridge and Macmillan Cancer Support.
Verified activity
Signals from 52North
4 published signals
Products & Services
52North delivered some shiny new boxes
Reported by 52North
Presence & Recognition
52North kicked off grant work with both Innovate UK and NIHR
Reported by 52North
Presence & Recognition
52North held regular meetings with NOME mentors Morten Faester, Kirsten Therkildsen, Søndersted-Olsen, Chelsea Ranger, Peter Birk, and Trond Johansen
Reported by 52North